Vor Ort
Merkzettel Warenkorb
  • Produktbild: Ageing and Dementia
  • Produktbild: Ageing and Dementia
Band 62 - 12%

Ageing and Dementia Current and Future Concepts

Aus der Reihe Journal of Neural Transmission. Supplementa
12% sparen

192,99 € UVP 219,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

20.08.2002

Herausgeber

Kurt Jellinger + weitere

Verlag

Springer Wien

Seitenzahl

384

Maße (L/B/H)

27,9/21/2,2 cm

Gewicht

892 g

Auflage

Softcover reprint of the original 1st ed. 2002

Sprache

Englisch

ISBN

978-3-211-83796-2

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

20.08.2002

Herausgeber

Verlag

Springer Wien

Seitenzahl

384

Maße (L/B/H)

27,9/21/2,2 cm

Gewicht

892 g

Auflage

Softcover reprint of the original 1st ed. 2002

Sprache

Englisch

ISBN

978-3-211-83796-2

Herstelleradresse

Springer Wien
Prinz-Eugen-Str. 8-10
1040 Wien
AT
buchhandel-buch@springer.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Ageing and Dementia
  • Produktbild: Ageing and Dementia
  • Contents Jellinger, K. A.: Vascular-ischernic dementia: an Update ................................................................... l van Dijk, E. J., Prins, N. D., Vermeer, S. E., Koudstaal, P. J., Breteler, M. M. B.: Frequency of white matter lesions and silent lacunar infarets ............................................................25 Kapeller, P., Schmidt, R., Enzmger, Ch., Ropele, S., Fazekas, F.: CT and MRI rating of white matter changes ....................................................................................................................41 Schmidt, R., Fazekas, F., Enzinger, C., Ropele, S., Kapeller, P., Schmidt, H.: Risk factors and progression of small vessel disease-related cerebral abnormalities ...................................................................................................................................47 Schmidt, H., Fazekas, F., Schmidt, R.: Microangiopathy-related cerebral damage and angiotensinogen gene: from epidemiology to biology ................................................................ 53 Fazekas, F., Ropele, S., Schmidt, R.: Can small-vessel disease-related cerebral abnormalities be used as a Surrogate marker for vascular dementia trials?...........................................61 Perry, G., Nimomura, A., Cash, A. D., Taddeo, M. A., Hirai, K., Aliev, G, Avila, J., Wataya, T., Shimohama, S., Atwood, C. S., Smith, M. A.: Reactive oxygen: its sources and significance in Alzheimer disease ................................................................. 69 Arendt T.: Dysregulation of neuronal differentiation and cell cycle control in Alzheimer's disease ..........................................................................................................................77 Kienzl, E., Jellinger, K., Janetzky, B., Steindl, H., Bergmann, J.: A broader horizon of Alzheimer pathogenesis: ALZAS - an early serum biomarker? ......................................................87 Smith, G.: ls mild cognitive impairment bridging the gap between normal aging and Alzheimer's disease?.......................................................................................................................... 97 Fischer, P., Jungwirth, S., Krampla, W., Weissgram, S., Kirchmevr, W., Schreiber, W., Huber, K., Rainer, M., Tragl, K. H.: Vienna-Transdanube-Aging 'VITA': study design, recruitment strategies and level of participation .........................................................105 Airnkvist, 0., Axelman, K., Basun, H., Wahlund, L.-O., Lannfelt, L.: Conversion from preclinical to clinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation ...........................................................117 Kurz, A., Riemenschneider, M., Drzezga, A., Lautenschlager, N.: The role of biological markers in the early and differential diagnosis of Alzheimer's disease .............................................................................................................................................127 Schmitt, F. A., Cragar, D., Ashford, J. W., Reisberg, B., Ferris, S., Möbius, H.-J., Stöffler, A.: Measuring cognition in advanced Alzheimer's disease for clinical trials......................... 135 Windisch, M., Hutter-Paier, B., Schreiner, E.: Current drugs and future hopes in the treatment of Alzheimer's disease..................................................................................................... 149 Flores-Flores, C., Nissirn, A., Shochat, S., Soreq, H.: Development of human anti- body fragments directed towards synaptic acetylcholinesterase using a semi- synthetic phase display library........................................................................................................ 165 Giacobini, E.: Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease